Eli Lilly and AbCellera’s SARS-CoV-2 neutralizing antibody Bamlanivimab (LY-CoV555) is making a significant impact in the fight against COVID-19.

Carterra’s high-throughput SPR technology allowed them to screen and characterize their entire library and understand the epitope relationship of their candidates as well as kinetics, affinity, and specificity.

“The resulting speed at which this drug discovery and development effort progressed, with achievement of first-in-human dose in only 90 days after the initiation of antibody screening, is a testament to the advanced discovery and characterization platforms.”

Read the Paper     Supplementary Materials